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OBJECTIVE: The purpose of this descriptive study was to
examine the most common treatment classes based on drug class
and the describe the differences in prescribing methods across age
groups. METHODS: Information was collected from the Phar-
Metrics Integrated Patient-centric Database, a large collection of
administrative claims. At the time of this analysis in 2004, there
weremore than 80 public and private health care plans included in
the database, representing approximately 9.6 million unique
patients. Analysis was performed using the Total Resource
Utilization (TRU) Benchmarks process, a descriptive methodol-
ogy organizes and separates information, from a third-party
database, into accessible benchmarks for comparison. These
resultswere then factored against age groups. The age group break
down is as follows: 12–14, 15–17, 18–24, and 24–35. RESULTS:
The most commonly prescribed medications in the United States
for acne were: New generation retinoid products, benzoyl
peroxide-based combo products , topical corticosteroids by Rx
only, Topical antibiotics, common topical retinoid products, oral
anti-biotics, as well as antidepressants and benzodiazepines in
some age categories. The age breakdown was as follows: Ages
12–14: Oral antibiotics (38.8%), Benzoyl peroxide-based prod-
ucts (32.7%), New generation retinoid products (30.1%), Topical
antibiotics (21.7%), Common topical retinoid products (20.7%)
Ages 15–17: Oral antibiotics (55.0%) Benzoyl peroxide-based
products (32.0%) New generation retinoid products (31.3%)
Topical antibiotics (21.3%), Common topical retinoid products
(21.1%) Ages 18–24: Oral antibiotics (52.6%), New generation
retinoid products (28.3%), Benzoyl peroxide-based products
(26.8%), Oral contraceptives (24.8%), Topical antibiotics
(20.4%) Ages 25–35: Oral antibiotics (44.2%), Oral contracep-
tives (33.0%), Topical antibiotics (22.1%), Benzoyl peroxide-
based products (21.5%), New generation retinoid products
(20.1%). CONCLUSION: It was determined that signiﬁcant dif-
ferences by medication type do in fact occur in all the different age
groups. The discrepancies can be clearly observed and on physi-
cian to physician bases, one can determine if their own particular
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OBJECTIVE: To evaluate the prevalence of chronic kidney
disease (CKD) in hospitalized patients and determine the propor-
tion of these patients with/without a diagnosis of CKD based on
estimated glomerular ﬁltration rates (eGFR). METHODS: A ret-
rospective analysis of US hospital data in the Cerner Health
Facts® database during January 2000 and March 2007 was
conducted. Inclusion criteria were age 18 years, a SCr measure-
ment 3–18 months before hospital admission and seven days
before or three days after hospital admission. Patients who had
dialysis, acute renal failure and/or mixed inpatient eGFR (some
values <60 and others =60 mL/min/1.73m2) were excluded. To
minimize bias and misclassiﬁcation due to hospitalization cir-
cumstances, 2 eGFR values <60 mL/min/1.73m2 were used to
designate patients with CKD. The ﬁrst eGFR was determined
from the closest SCr measurement within 3–18 months before
hospitalization and the second eGFR was determined using a
SCr seven days before or three days of hospital admission. The
MDRD-4 equation was used to calculate eGFR. RESULTS: Of
the 1,265,014 patients hospitalized over the seven years evalua-
tion, 193,221 met the inclusion criteria. Approximately 21% of
patients were subsequently excluded for dialysis, acute renal
failure, and/or mixed eGFR (n = 40,937). Overall, 27% of
patients (n = 41,495) had an eGFR < 60 mL/min/1.73m2 at
admission. Of these, 81% (n = 33,443) had an eGFR < 60 mL/
min/1.73m2 prior to admission. Of this subset likely to have CKD
based on chronically low eGFR, only 26% (n = 8,560) had a
diagnosis of CKD at admission based on ICD-9-CM diagnosis.
CONCLUSION: Our ﬁndings suggest that most patients with
RKF upon hospital admission may have CKD. Of these, few
seem to have supportive CKD diagnosis codes. Identiﬁcation and
diagnosis of this patient population during hospitalization may
provide a unique opportunity to improve disease management
during the inpatient stay or after discharge, and may result in
earlier nephrology referrals if appropriate.
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OBJECTIVE: To determine the association of blood pressure
(BP) control and trajectory of renal function over seven years in
a cohort of hypertensive veterans; and to determine the associa-
tion between different classes of antihypertensive medications
and renal function quantiﬁed by glomerular ﬁltration rate (GFR).
METHODS: Data were obtained from Southern Arizona Veter-
ans’ Affairs Health Care System from January 1, 2000 through
December 31, 2006. Inclusion criteria consisted of veterans 21
and < 90 years of age with at least two systolic BP measurements,
and two serum creatinine measurements at least 90 days apart
who had an ICD-9 hypertension diagnosis. Veterans were
divided into time-varying controlled or uncontrolled hyperten-
sion groups based upon JNC-7 deﬁnitions. Factors examined
included age, sex, race/ethnicity membership, and antihyperten-
sive medication use. Medication categories included angiotensin
converting enzyme inhibitor (ACE), beta-blocker (BB), or
calcium channel blocker (CCB) monotherapy, or combinations of
ACE, BB, and CCB. GFR was estimated using serum creatinine
level, age, sex, and race/ethnicity. Analysis was performed using
a generalized linear mixed model with patient as random effect.
RESULTS: A total of 25,819 subjects met inclusion/exclusion
criteria: 12,411 with controlled and 13,406 with uncontrolled
BP. Males comprised 11,669 of controlled and 12,864 of uncon-
trolled groups. Mean age (SD) at index was 64.9(11.9) and
66.6(11.6) years in the controlled and uncontrolled groups
respectively. Annual decline in GFR was 0.32 ml/–/1.73m2 after
adjusting for covariates and medication use. There was a signiﬁ-
cant interaction between BP control and age (p < 0.001). ACE,
BB, CCB use was associated with higher GFR (1.1, 95% CI
0.7–1.4; 0.5, 95% CI 0.1–0.8; and 0.8, 95% CI 0.2–1.3 ml/
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minute/1.73m2, respectively). CONCLUSION: This analysis
identiﬁed a signiﬁcant decrease in GFR over time. Persons with
controlled BP taking antihypertensive therapy had higher GFR
than those taking no medication suggesting that antihypertensive
medication use preserves kidney function.
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OBJECTIVE: Failure to dose adjust for renal insufﬁciency during
hospitalization can be a common cause for medication errors and
are an important function for clinicians. We examined the preva-
lence, mortality and length of stay (LOS) for cases that exhibited
changes in renal function during hospitalization. METHODS:
We retrospectively analyzed 1,011,055 non-dialysis admissions
who had at least two serum creatinine values during hospital stay
across 74 hospitals that provided electronic laboratory results
from 2003–2006. We used a modiﬁed Cockcroft-Gault (140-
age)/SCr (x 0.85 for females) to determine baseline and changing
creatinine clearance (eCrCl, ml/min). Cases were stratiﬁed based
on eCrCl as normal ( 81 ml/min), mild (50–80 ml/min), mod-
erate (16–49 ml/min), and advanced (15 ml/min). Worsening
or improvement was deﬁned as cases that moved one or more
eCrCl strata to another during hospitalization. Unadjusted hos-
pital mortality (95% CI) and median LOS were evaluated.
RESULTS: On admission 29.6% had normal, 34.4% had mild,
34.1% had moderate, and 1.9% had advanced eCrCl. Of these
cases the eCrCl remained the same in 79.2%, worsened in 11.6%
and improved in 9.2%. Mortality and median LOS was highest
for worsening eCrCl (7.9 [CI:7.8–8.1] and 6 days) followed by
those remaining the same (2.8 [CI:2.8–2.9] and 4 days) and those
with improving eCrCl (1.8 [CI:1.7–1.9] and 4 days). Cases with
 2 strata worsening in eCrCl (0.5% of cases) had higher mor-
tality and LOS (25.9 [CI:24.7–27.1] and 10 days) than those
with moderate (5.0 [CI:4.9–5.1] and 5 days, 28.8% of cases) or
advanced (13.3 [CI:12.7–13.8] and 5 days, 1.5% of cases) eCrCl
that remained the same. CONCLUSION: Both improvement and
worsening renal function necessitating potential dosage adjust-
ment are common during hospitalization. Mortality and LOS is
higher for cases that had worsening renal function. Comprehen-
sive renal dosing programs have the potential of improving medi-
cation safety and related outcomes.
URINARY/KIDNEY DISORDERS—Cost Studies
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OBJECTIVE: The treatment of chronic kidney disease (CKD)
with dialysis is associated with the appearance of hyperphos-
phatemia, which contributes to the presence of vascular calci-
ﬁcations, thus increasing the probability of the occurrence of
cardiovascular events and death in these patients. The objective
of this analysis was to evaluate the incremental cost-
effectiveness of the use of sevelamer to manage hyperphos-
phatemia secondary to CKD from an institutional perspective.
METHODS: A Markov model was created in TreeAge to esti-
mate the costs and beneﬁts of the treatment with sevelamer or
calcium tablets in patients with renal failure considering a tem-
porary horizon of 60 months. The transition probabilities were
taken from clinical trials identiﬁed through a systematic review
of literature. The effectiveness measure considered was an
increase in patient survival. Data related to the use of resources
were obtained from a nominal group and cost information was
obtained from price lists and rates published by health institu-
tions. In addition a univariate sensitivity analysis was per-
formed on the probability of death for sevelamer group. Costs
were estimated using 2007 prices and are expressed in US
dollars (exchange rate of 10.93 pesos per US dollar).
RESULTS: Survival of patients with CKD increased in 18.4%
in the sevelamer group, compared to the calcium group
(83.12% vs. 64.72%). The expected average monthly cost
was $639 for calcium and $989.50 for sevelamer. The Cost-
Effectiveness Ratio of sevelamer and calcium was $1068 and
$777.70, respectively, and the Incremental Cost-Effectiveness
Ratio for the implementation of sevelamer vs. calcium was
$3343.50. CONCLUSION: Sevelamer is a cost-effective drug
for the treatment of hyperphosphatemia in patients with
chronic kidney disease in the Mexican context.
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OBJECTIVE: To determine the incremental cost-effectiveness
ratio (ICER) of cinacalcet as an adjuvant therapy for SHPT
from the perspective of the Portuguese NHS. METHODS: A
probabilistic Markov model was used to compare best standard
care (BSC) with BSC plus cinacalcet. The model was developed
in cycles of six months until the death of all patients. Patients
were distributed according to the risk of hospital admission due
to cardiovascular events, major or minor fractures and parathy-
roidectomies. The absence of events and/or death was also
considered. The probabilities of SHPT’s complications were
obtained from the literature. Portuguese ofﬁcial mortality rates
were weighted by the presence of renal insufﬁciency and by the
PTH levels. Due to lack of alternative, the resources used (only
direct medical costs) were estimated by a Delphi panel of eight
nephrologists and by a physical medicine and rehabilitation
specialist. Unit costs were obtained from Portuguese ofﬁcial
sources. Market shares of medicines prescribed in outpatient
services were selected from the IMS. RESULTS: Cinacalcet
increases 0.4 life years (LY) per patient with SHPT. The use of
cinacalcet saves hospital admissions and follow-up costs of sec-
ondary events, but is associated with an ICER of €53,682 per
LY gained. However, if dialysis costs are not considered, the
ICER is €32,374 per LY gained and the probability of being
cost-effective increases from 61% to 83% if acceptability for
reimbursement is limited at €50.000 per LY gained. CONCLU-
SION: Using a €50,000 WTP threshold, cinacalcet was found
cost-effective if the increased cost of dialysis was excluded. The
inclusion of this cost (induced by a longer life expectancy) leads
to an ICER of €53,682 per LY gained. A clear paradox arises
here as the alternative becomes less cost-effective by increasing
dialysis patients’ longevity.
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